Results 91 to 100 of about 8,636 (197)

Clinical case of thrombotic microangiopathy in obstetric practice

Сеченовский вестник, 2017
Trombotic microangiopathy is heterogeneous group of the diseases united by a community of a histological and clinical implications at difference of pathogenetic mechanisms, presents clinical-morphological syndrome characterizing a lesion of vessels of a ...
M. N. Mochalova, T. E. Belokrinitskaya, T. V. Haven, E. M. Shifman, K. G. Shapovalov, S. V. Kostromitin   +5 more
doaj  

A Case of Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome

Annals of Internal Medicine: Clinical Cases
Atypical hemolytic uremic syndrome (aHUS) is a rare non-Shiga toxin thrombotic microangiopathy caused by uncontrolled activation of the alternative complement pathway.
Kwasi Opare-Addo, Sammudeen Ibrahim, Basilio Addo, Jorge Chancay Rodriguez   +3 more
doaj   +1 more source

ATYPICAL HEMOLYTIC-UREMIC SYNDROME IN THE FEMALE PATIENT WITH CONCURRENT MENOMETRORRHAGIA (clinical case)

Вестник анестезиологии и реаниматологии, 2018
The article describes the follow-up over the development of atypical hemolytic-uremic syndrome in the female patient suffering menometrorrhagia which manifested with concurrent metrorrhagia and was accompanied with acute renal failure.
A. V. Pyregov, T. A. Fedorova, A. Yu. Korolev, K. I. Grischuk   +3 more
doaj   +1 more source

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

British Journal of Pharmacology, Volume 183, Issue 11, Page 2874-2889, June 2026.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva, Guido Junge, Kenneth Kulmatycki, Robert Schmouder, Anna Schubart, Marie‐Anne Valentin   +5 more
wiley   +1 more source

Current treatment of atypical hemolytic uremic syndrome

Intractable & Rare Diseases Research, 2014
Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.).
S. Kaplan, Bernard, L. Ruebner, Rebecca, M. Spinale, Joann, Copelovitch, Lawrence   +3 more
openaire   +3 more sources

Common Hematologic Emergencies—Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias—A Pivotal Role of Clinical Laboratory

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 521-530, June 2026.
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova, Nicolas Ulrich Edgar, Anton V. Rets   +2 more
wiley   +1 more source

Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. [PDF]

, 2009
Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency ...
이재승
core   +1 more source

Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1303-1304, June 2026.
Lea Gerischer, Jutta Schroeder‐Braunstein, Guido Wabnitz, Andreas Meisel   +3 more
wiley   +1 more source

[Hemolytic uremic syndrome with an atypical presentation].

Revue medicale de Liege, 2010
The hemolytic uremic syndrome (HUS) is rare and of guarded prognosis in adults. It expresses a renal thrombotic microangiopathy. We report the case of a young patient whose clinical presentation and exploration make a diagnosis of HUS likely. The atypical presentation provides an opportunity not only to discuss all diagnostic elements based on recent ...
NOGUE KAMDJE, Alain, BRASSEUR, Edmond, fournier,, D'Orio, Vincenzo   +3 more
openaire   +2 more sources

An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment

Hematology Reports, 2018
Atypical hemolytic uremic syndrome is a rare and progressive disease caused by uncontrolled alternative complement activation. Dysregulatıon of the complement activation results in thrombotic microangiopathy and multiorgan damage.
Serife Solmaz Medeni, Sinem Namdaroglu, Tugba Cetintepe, Can Ozlu, Funda Tasli, Zehra Hilal Adibelli, Oktay Bilgir, Erhan Tatar   +7 more
doaj   +1 more source